Xgene Pharmaceutical Secures $35M Series D Funding to Advance Non-Opioid Pain Therapy XG005 into Phase III Trials in the US
Xgene Pharmaceutical Inc. announced the successful completion of a RMB 250 million ($35 million) Series...
Xgene Pharmaceutical
Xgene Licenses Novel Non-Opioid Analgesic XG005 to NeuroGen for Greater China Development
Shanghai-based Xgene Pharmaceutical Inc. has entered into a licensing agreement withNeuroGen Pharma, a neurology care...